Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $101.4M | 22 | 99.2% |
| Consulting Fee | $579,843 | 24 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $209,253 | 2 | 0.2% |
| Travel and Lodging | $38,504 | 8 | 0.0% |
| Food and Beverage | $1,406 | 28 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $101.4M | 22 | $0 (2023) |
| Gilead Sciences, Inc. | $461,877 | 34 | $0 (2024) |
| Tarsus Pharmaceuticals, Inc. | $228,003 | 11 | $0 (2024) |
| Amicus Therapeutics, Inc. | $139,060 | 16 | $0 (2020) |
| Ultragenyx Pharmaceutical Inc. | $65.46 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $689,946 | 46 | Gilead Sciences, Inc. ($461,877) |
| 2023 | $2.5M | 6 | PFIZER INC. ($2.5M) |
| 2022 | $98.9M | 16 | PFIZER INC. ($98.9M) |
| 2020 | $51,616 | 8 | Amicus Therapeutics, Inc. ($51,616) |
| 2019 | $87,444 | 8 | Amicus Therapeutics, Inc. ($87,444) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 2 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/31/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.95 | General |
| 07/31/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.95 | General |
| 07/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $124.89 | General |
| 07/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $44.75 | General |
| 07/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.95 | General |
| 07/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.95 | General |
| 06/25/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $21,598.36 | General |
| 05/08/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Dividend, profit or other return on investment | $149,995.16 | General |
| 05/08/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Stock, stock option, or any other ownership interest | $149,965.20 | General |
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $48.75 | General |
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.95 | General |
| 05/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.95 | General |
| 05/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $120.53 | General |
| 05/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $44.75 | General |
| 05/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.95 | General |
| 05/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.95 | General |
| 04/02/2024 | Tarsus Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $105,793.00 | General |
| 04/02/2024 | Tarsus Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $103,460.00 | General |
| 03/26/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,090.16 | General |
| 02/02/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Dividend, profit or other return on investment | $39,444.74 | General |
| 02/02/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Stock, stock option, or any other ownership interest | $39,403.52 | General |
| 12/14/2023 | PFIZER INC. | — | Acquisitions | Cash or cash equivalent | $974,395.00 | General |
| 12/14/2023 | PFIZER INC. | — | Acquisitions | Cash or cash equivalent | $468,076.00 | General |
| 12/14/2023 | PFIZER INC. | — | Acquisitions | Cash or cash equivalent | $343,228.12 | General |
| 12/14/2023 | PFIZER INC. | — | Acquisitions | Cash or cash equivalent | $299,622.80 | General |
About Dr. Ted Love, M.D
Dr. Ted Love, M.D is a Cardiovascular Disease healthcare provider based in Hillsborough, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/25/2013. The National Provider Identifier (NPI) number assigned to this provider is 1417299728.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ted Love, M.D has received a total of $102.2M in payments from pharmaceutical and medical device companies, with $689,946 received in 2024. These payments were reported across 84 transactions from 5 companies. The most common payment nature is "Acquisitions" ($101.4M).
Practice Information
- Specialty Cardiovascular Disease
- Location Hillsborough, CA
- Active Since 03/25/2013
- Last Updated 03/25/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417299728
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.